Skip to content
Clinical Trials – home

Pneumococcal Polysaccharide Serotype 14 Vaccine: What Patients Should Know

4 / 12
trials open to patients / all trials
22+
Countries

In short

This article summarizes key clinical trials investigating the safety and efficacy of pneumococcal vaccines containing polysaccharide serotype 14, an important component in preventing pneumococcal infections. The trials examine various pneumococcal vaccine formulations in different populations, including healthy adults, children, and those at increased risk of pneumococcal disease. The studies aim to evaluate immune responses, safety profiles, and potential for disease prevention across age groups.

What is the pneumococcal polysaccharide serotype 14 vaccine?

The pneumococcal polysaccharide serotype 14 vaccine is a component of broader pneumococcal vaccines that help protect against infections caused by the Streptococcus pneumoniae bacteria, also known as pneumococcus. This particular serotype (type 14) is one of many pneumococcal strains that can cause serious illnesses.

Pneumococcal vaccines containing serotype 14 are often referred to by brand names like Prevnar 13, Prevenar 13, Synflorix, or Apexxnar, depending on the specific formulation. These vaccines may protect against multiple pneumococcal serotypes, including type 14.

How does it work?

The vaccine works by introducing a small amount of the outer coating (polysaccharide) of the pneumococcal bacteria into your body. This coating is specific to serotype 14. Your immune system recognizes this as foreign and produces antibodies against it. If you're later exposed to the actual pneumococcus bacteria of this serotype, your body can quickly recognize and fight off the infection.

In many pneumococcal vaccines, the polysaccharide is attached (conjugated) to a harmless protein. This process, called conjugation, helps improve the immune response, especially in young children.

Who needs this vaccine?

Pneumococcal vaccines containing serotype 14 are recommended for several groups:

  • All children under 2 years old
  • Adults 65 years and older
  • People with certain medical conditions that increase their risk of pneumococcal disease, such as:
    • Chronic heart, lung, or liver diseases
    • Diabetes
    • Weakened immune systems

Your healthcare provider can advise if you or your child should receive this vaccine based on age, health status, and previous vaccinations.

What are the benefits?

Vaccination against pneumococcal serotype 14 can help prevent serious infections caused by this strain, including:

  • Pneumonia: An infection of the lungs
  • Bacteremia: A blood infection
  • Meningitis: An infection of the lining of the brain and spinal cord
  • Otitis media: Middle ear infections (especially in children)

These infections can be life-threatening, particularly in young children, older adults, and people with weakened immune systems. By getting vaccinated, you reduce your risk of these serious illnesses.

Is it safe?

Pneumococcal vaccines, including those containing serotype 14, have been extensively studied and are considered very safe. They have been used for many years in millions of people worldwide. The benefits of protection against pneumococcal disease far outweigh the small risk of side effects for most people.

What are the potential side effects?

Most side effects of pneumococcal vaccines are mild and go away on their own within a few days. Common side effects may include:

  • Pain, redness, or swelling at the injection site
  • Mild fever
  • Irritability (in children)
  • Fatigue
  • Headache
  • Muscle pain

Serious allergic reactions are very rare but can occur. Seek immediate medical attention if you experience difficulty breathing, rapid heartbeat, dizziness, or severe swelling after receiving the vaccine.

How is it administered?

The pneumococcal vaccine containing serotype 14 is typically given as an injection into the muscle (intramuscular). For infants, it's usually injected into the thigh muscle. For older children and adults, it's often given in the upper arm.

The number of doses and timing can vary depending on the specific vaccine and the person's age and health status. For example:

  • Infants usually receive a series of doses starting at 2 months of age
  • Adults 65 and older may receive a single dose
  • People with certain health conditions may need additional doses

Always follow your healthcare provider's recommendations for vaccination schedules.

Questions people often ask

Conditions where Pneumococcal Polysaccharide Serotype 14 is being studied

Each condition opens its own overview and trial list

Trials with Pneumococcal Polysaccharide Serotype 14

Recruiting trials first

See all 12 →
Quick filters
  • Participants:Adults
  • Participants:Children · Healthy volunteers
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).